CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
ATM, Ataxia telangiectasia mutated
ATR, Ataxia telangiectasia and Rad3 related
CRT, Chemoradiotherapy
CT, Computed tomography
CTCAE, Common terminology criteria for adverse events
CTRad, Clinical and Translational Radiotherapy Research Working Group
Continual reassessment method
DDRi, DNA damage response inhibitor
DLT, Dose limiting toxicity
DNA damage repair inhibitor
DNA, Deoxyribonucleic acid
DNA-PK, DNA-dependent protein kinase
ECOG, Eastern Cooperative Oncology Group
EORTC, European Organisation for Research and Treatment of Cancer
ICRU, International Commission on Radiation Units and Measurements
IMPs, Investigational medicinal products
LA, Locally advanced
MRC, Medical Research Council
NCRI, National Cancer Research Institute
NSCLC, Non-small cell lung cancer
Non-small cell lung cancer
PARP, Poly (ADP-ribose) polymerase
PET, Positron emission tomography
PFS, Progression free survival
PROMs, Patient-reported outcome measures
Platform trial
RECIST, Response evaluation criteria in solid tumours
RP2D, Recommended phase II dose
RT, Radiotherapy
SACT, Systemic anti-cancer therapy
SRC, Safety review committee
Sequential chemoradiotherapy
TNM, Tumour node metastasis
TiTE-CRM, Time to event continual reassessment method
cfDNA, Cell-free DNA
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
21
04
2020
revised:
15
09
2020
accepted:
15
09
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.
Identifiants
pubmed: 33072895
doi: 10.1016/j.ctro.2020.09.006
pii: S2405-6308(20)30078-1
pmc: PMC7548952
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61-66Subventions
Organisme : Medical Research Council
ID : G0802755
Pays : United Kingdom
Organisme : Medical Research Council
ID : G108/589
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_12006
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00001/6
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362
pubmed: 32107107
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Radiother Oncol. 2013 Oct;109(1):8-12
pubmed: 24094626
Signal Transduct Target Ther. 2020 May 1;5(1):60
pubmed: 32355263
Stat Med. 2003 Jul 30;22(14):2239-56
pubmed: 12854091
Clin Oncol (R Coll Radiol). 2016 Nov;28(11):720-725
pubmed: 27591000
Ann Oncol. 2009 Jan;20(1):98-102
pubmed: 18718891
Biometrics. 2000 Dec;56(4):1177-82
pubmed: 11129476
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):487-9
pubmed: 25304944
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Transl Radiat Oncol. 2017 Nov 21;8:12-16
pubmed: 29594237
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Br J Cancer. 2016 May 24;114(11):1199-205
pubmed: 27140316
Mol Cancer Res. 2018 Feb;16(2):222-232
pubmed: 29133592
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):688-696
pubmed: 31514942
Front Oncol. 2019 Oct 10;9:1009
pubmed: 31649878
Lancet Oncol. 2010 May;11(5):459-64
pubmed: 20378407
Clin Cancer Res. 2015 Jul 1;21(13):2898-904
pubmed: 26133775
Br J Radiol. 2016;89(1060):20150431
pubmed: 26838950
J Thorac Cardiovasc Surg. 2018 Jan;155(1):356-359
pubmed: 29061464
Nat Rev Clin Oncol. 2016 Oct;13(10):627-42
pubmed: 27245279
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
Ann Oncol. 2017 Nov 01;28(11):2874-2881
pubmed: 28945875
Clin Chest Med. 2011 Dec;32(4):605-44
pubmed: 22054876
Radiother Oncol. 2017 Sep;124(3):475-481
pubmed: 28697853
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Eur J Gynaecol Oncol. 2010;31(4):386-91
pubmed: 20882878
Lung Cancer. 2001 Apr;32(1):27-38
pubmed: 11282426
BMJ Open. 2016 Apr 15;6(4):e010457
pubmed: 27084277
Radiat Oncol. 2017 Dec 29;12(1):208
pubmed: 29287602
Gynecol Oncol. 2017 Mar;144(3):486-490
pubmed: 28109627
Cancer Treat Res Commun. 2018;16:9-12
pubmed: 31299005
J Clin Oncol. 2010 May 1;28(13):2181-90
pubmed: 20351327
J Clin Oncol. 2016 Dec 20;34(36):4371-4380
pubmed: 27601554
J Clin Oncol. 2020 Mar 1;38(7):706-714
pubmed: 31841363
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):733-742
pubmed: 31809876
Clin Cancer Res. 2019 Mar 1;25(5):1455-1461
pubmed: 30498095
Radiother Oncol. 2014 May;111(2):228-36
pubmed: 24857596
Clin Cancer Res. 2018 Oct 15;24(20):4949-4959
pubmed: 30084837
Br J Cancer. 2016 Oct 25;115(9):1147-1155
pubmed: 27727232
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Radiother Oncol. 2004 May;71(2):139-46
pubmed: 15110446
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Radiother Oncol. 2010 Apr;95(1):32-40
pubmed: 19733410